Table 1.

Demographic and clinical characteristics of study population.

	Included in study (n, column percentage)	Initiated on treatment (n, column percentage)	Percentage initiated on treatment (%)
Total sample	15121	477	3.15
Age category
18 – 30 years	4884 (32.3%)	116 (24.3%)	2.38
31 – 40 years	4854 (32.1%)	176 (36.9%)	3.63
41 years and above	5383 (35.6%)	185 (38.8%)	3.31
Sex
Male	6081 (40.2%)	263 (55.1%)	4.32
Female	9040 (59.8%)	214 (44.9%)	2.37
History of prior TB
Yes	2195 (14.5%)	103 (21.6%)	4.69
No	12648 (83.7%)	368 (77.1%)	2.90
Unknown	278 (1.8%)	6 (1.3%)	2.16
Reported cough
None	6481 (42.9%)	81 (17.0%)	1.25
Yes	8640 (57.1%)	396 (83.0%)	4.58
Reported night sweats
None	10341 (68.4%)	222 (46.5%)	2.15
Yes	4780 (31.6%)	255 (53.5%)	5.33
Reported fever
None	10287 (68.0%)	240 (50.3%)	2.33
Yes	4834 (32.0%)	237 (49.7%)	4.90
HIV
Negative	3101 (20.5%)	90 (18.9%)	2.90
Positive, not on ART	7600 (50.3%)	237 (49.7%)	3.11
Positive, on ART	2424 (16.0%)	104 (21.8%)	4.30
Unknown	1996 (13.2%)	46 (9.6%)	2.30
Study year
2011 – 2013	9915 (65.6%)	350 (73.4%)	3.53
2014 – 2017	2138 (14.1%)	40 (8.4%)	1.87
2018 – 2020	3068 (20.3%)	87 (18.3%)	2.84
Country
Belarus	97 (0.6%)	1 (0.2%)	1.03
Botswana	5838 (38.6%)	132 (27.7%)	2.26
Brazil	272 (1.8%)	5 (1.0%)	1.84
Ethiopia	173 (1.1%)	2 (0.4%)	1.16
Georgia	300 (2.0%)	6 (1.3%)	2.00
Ghana	121 (0.8%)	6 (1.3%)	4.96
India	1062 (7.0%)	23 (4.8%)	2.17
Kenya	290 (1.9%)	16 (3.4%)	5.52
Papua New Guinea	112 (0.7%)	4 (0.8%)	3.58
Peru	298 (2.0%)	5 (1.0%)	1.68
South Africa	5877 (38.9%)	168 (35.2%)	2.86
Uganda	291 (1.9%)	43 (9.0%)	14.78
Zimbabwe	390 (2.6%)	66 (13.8%)	16.92